Area of research
Oncology · Epidemiology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Autophagy in Disease and Therapy, Immunotherapy and Immune Responses, and CAR-T cell therapy research.
Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis.
Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside.
Metabolism and mRNA translation: a nexus of cancer plasticity.
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study).
Illuminating a Dark Kinase in the Mesenchymal Cancer Cell State.
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.
Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer.
Plasma proteometabolome in lung cancer: exploring biomarkers through bidirectional Mendelian randomization and colocalization analysis.
EIF6 conditions drug-tolerant persister-like transdifferentiation in small cell lung carcinoma
Reflections on Advances in Cancer Research in 2024.
Drug-tolerant persister cells in cancer: the cutting edges and future directions.
Immunotherapy for Recurrent Glioma-From Bench to Bedside.
Spatial patterns of the cap-binding complex eIF4F in human melanoma cells.
The multiple roles of LDH in cancer
The multiple roles of LDH in cancer.
A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour CD8<sup>+</sup> T cell immune response.
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.
Editorial: Non-genetic adaptive drug resistance in cancer.
The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance.
<i>In situ</i> detection of the eIF4F translation initiation complex in mammalian cells and tissues.
Persistent Cancer Cells: The Deadly Survivors.
Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation.
Cell plasticity in cancer cell populations.
Engineering a Circular Riboregulator in <i>Escherichia coli</i>.
Emerging role of mRNA epitranscriptomic regulation in chemoresistant cancer cells.
An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells
An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.